| Clinical data | |
|---|---|
| Pronunciation | /ɛˈpoʊ.ɪtɪn/ |
| Trade names | Neorecormon, Betapoietin, others[1] |
| AHFS/Drugs.com | International Drug Names |
| License data | |
| Pregnancy category |
|
| Routes of administration | Intravenous, subcutaneous |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
  (what is this?) (verify) | |
Epoetin beta (INN), sold under the brand name Neorecormon among others, is a synthetic, recombinant[4] form of erythropoietin, a protein that promotes the production of red blood cells. It is an erythropoiesis-stimulating agent (ESA) that is used to treat anemia, commonly associated with chronic kidney failure and cancer chemotherapy.
It is on the World Health Organization's List of Essential Medicines.[5]
- ^ Centers for Medicare and Medicaid Services: Erythrocyte Stimulating Agents Archived 2017-06-07 at the Wayback Machine. Retrieved 15 February 2017.
- ^ a b Australian product information Archived 2023-01-09 at the Wayback Machine guildlink.com.au
- ^ "NeoRecormon EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 9 January 2023. Retrieved 9 January 2023.
- ^ Dunn CJ, Markham A (February 1996). "Epoetin beta. A review of its pharmacological properties and clinical use in the management of anaemia associated with chronic renal failure". Drugs. 51 (2): 299–318. doi:10.2165/00003495-199651020-00008. PMID 8808169. S2CID 46985336.
- ^ World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.